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Major histocompatibility complex (MHC)-I and MHC-II molecules play an essential role in
the immune response to pathogens by virtue of their ability to present peptides to CD8+
and CD4+ T cells, respectively. Given this critical role, MHC-I and MHC-II genes are regu-
lated in a tight fashion at the transcriptional level by a variety of transcription factors that
interact with conserved cis-acting regulatory promoter elements. In addition to the activ-
ities of these regulatory factors, modiﬁcation of chromatin also plays an essential role in
the efﬁcient transcription of these genes to meet with local requirement for an effective
immune response.The focus of this review is on the transcription factors that interact with
conserved cis-acting promoter elements and the epigenetic mechanisms that modulate
induced and constitutive expression of these MHC genes.
Keywords: MHC-I, MHC-II, CIITA, transcription, epigenetics
INTRODUCTION
The products of the MHC class I (MHC-I) and MHC class II
(MHC-II) genes encode cell-surface glycoproteins involved in the
binding andpresentation of peptides to theT cell receptors (TCRs)
of T lymphocytes. Major histocompatibility complex (MHC)-I
proteins present peptides from endogenous sources, such as those
derived from viruses, to CD8+ T cells, whereas MHC-II molecules
mainly present peptides from exogenous sources, such as those
derived from extracellular pathogens, to CD4+ T cells. These tri-
molecular interactions of MHC, peptide, and TCR are central to
the generation of antigen-speciﬁc immune responses.
The MHC-I gene cluster encodes the highly polymorphic clas-
sicalMHC-Imolecules (human leukocyte antigen,HLA-A, -B, and
-C), which play essential roles in the detection and elimination of
virus-infected cells, tumor cells and transplanted allogeneic cells
and the less polymorphic non-classical MHC-Ib molecules (HLA-
E, -F, and -G). These latter MHC-Ib molecules have specialized
immune regulatory functions (Van den Elsen et al., 2004). All cell-
surface expressed MHC-I and MHC-Ib molecules are associated
with the non-polymorphic β2-microglobulin.
The MHC-II genes encode the polymorphic HLA-DR, -DQ,
and -DP molecules, which are expressed as α- and β-chain het-
erodimers on the cell surface. MHC-II molecules are central in
the initiation of cellular and humoral immune responses, but they
have also been implicated as contributing factors for a variety of
autoimmune disorders. In contrast to the classical MHC-I mole-
cules, which are expressed in a constitutive fashion on almost all
nucleated cells, the constitutive expression of MHC-II molecules
is tissue-speciﬁc and is restricted to professional antigen present-
ing cells (APCs, i.e., dendritic cells, macrophages, and B cells) and
in thymic epithelial cells (Van den Elsen et al., 2004). All other
cell types lack constitutive expression of MHC-II molecules, but
their expression can be induced by exposure to cytokines of which
interferon γ (IFNγ) is the most potent, or upon activation, such as
in human T cells (Holling et al., 2002; Wong et al., 2002). Because
of their crucial role in the immune response, the genes encod-
ing MHC-I and MHC-II molecules are tightly regulated at the
transcriptional level both by genetic and epigenetic mechanisms.
TRANSCRIPTIONAL REGULATION OF MHC GENES
Activation of MHC-I genes, with the exception of HLA-G, is
mediated by several conserved cis-acting regulatory promoter
elements: i.e., the enhancer A, interferon-stimulated response ele-
ment (ISRE) and the SXY-module (comprising the S/W, X1, X2,
and Y-boxes; Figure 1). These conserved regulatory elements play
an important role in the inducible and constitutive expression of
MHC-I genes (Van den Elsen et al., 2004). Interestingly, these reg-
ulatory elements are also involved in the transcriptional activation
of the β2-microglobulin promoter but not of the promoters of the
genes encoding the transporter associated with antigen process-
ing (TAP) and the large multifunctional protease (LMP), which
are essential components in the MHC-I antigen processing and
presentation pathway (Gobin et al., 1997, 2001; Van den Elsen
et al., 2004). In MHC-I promoters, the enhancer A is bound by
nuclear factor (NF)-κB,while the ISRE is bound by interferon reg-
ulatory factor (IRF) family members (Figure 1; Gobin et al., 1998,
1999). The transcription factors NF-κB and IRF-1 are mediators
of the TNFα and IFNγ (Janus-family kinase/signal transducer and
activator of transcription, Jak/STAT) routes of gene activation,
respectively, which account for the induced MHC-I transcription.
Additionally, binding sites for upstream-stimulatory factor (USF)-
1, -2 and for the transcription factor Sp-1 can also be found within
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FIGURE 1 | Schematic overview of the elements, interacting factors
and epigenetic events governing MHC-I and MHC-II transcription.
Shown is the shared proximal SXY-module, and the upstream enhancer A
and ISRE typical for MHC-I promoters with the exception of HLA-G. The
proximal SXY-module is bound by the MHC-enhanceosome.
these upstream regulatory promoter elements in a locus and allele-
speciﬁc fashion (Figure 1; Gobin et al., 1998, 1999). As a result of
nucleotide sequence variation in the enhancer A and the ISRE in
the different MHC-I promoters the level of promoter activation
induced by these pathways differs among the various MHC-I loci
(Gobin et al., 1998, 1999; Girdlestone, 2000; Johnson, 2003).
Expression of HLA-G is under normal circumstances conﬁned
primarily to fetal trophoblast cells and thymic epithelium. This
suggest an alternative transcriptional control of HLA-G than that
of the classical MHC-I genes. Indeed, while encoding similar
regulatory elements in its 5′ DNA, HLA-G is not regulated by
the upstream ISRE and κB sites or the SXY regulatory module
(Gobin and Van den Elsen, 1999). Instead, the HLA-G promoter
can be transactivated by the cyclic-AMP response element bind-
ing protein (CREB)-1 (Gobin et al., 2002). This transactivation
is mediated by further upstream positioned CRE sites, which can
bind CREB-1, activating transcription factor (ATF)-1 and c-Jun
in vitro (Figure 1; Gobin et al., 2002). Since these factors are ubiq-
uitously expressed, the lack of HLA-G expression in cell types other
than trophoblast cells must be regulated in a different manner
such as by alternative regulatory factors that suppress expression
of HLA-G or by epigenetic mechanisms. In this respect it was
recently shown that Ras-responsive binding protein-1 (RREB-1)
is a transcriptional repressor of HLA-G, which exerts its function
through chromatin remodeling of the HLA-G locus by virtue of
its interaction with subunits of the CtBP complex in cells that lack
expressionof HLA-G (Flajollet et al., 2009).Additionally, it has also
been demonstrated that treatment of various types of cells lacking
HLA-G expression with the DNA methyltransferase inhibitor 5′-
AZA-deoxycytidine results in restoration of HLA-G transcription
(Moreau et al., 2003). Besides DNA methylation, histone acetyla-
tionmodiﬁcations have also been implicated in the transcriptional
control of HLA-G in trophoblast cell lines (Holling et al., 2009).
The SXY-module is also present is the promoters of MHC-II
and its accessory genes (invariant chain,HLA-DM and HLA-DO).
However, MHC-II promoters differ from MHC-I promoters in
that they lack the typical enhancer A and ISRE (Figure 1). The
sequence and stereo-speciﬁc alignment of the various boxes in the
SXY-module is highly conserved and critical for its functioning
in constitutive and inducible-transcriptional activation of MHC-
I and MHC-II genes (Gobin et al., 2001; Ting and Trowsdale,
2002). The SXY-module is cooperatively bound by a multi-protein
complex containing regulatory factor X (RFX; consisting of RFX5,
RFXB/ANK, and RFXAP; Steimle et al., 1995; Durand et al., 1997;
Masternak et al., 1998;Nagarajan et al., 1999),CREB/ATF (Moreno
et al., 1999; Gobin et al., 2001), and nuclear factor-Y (NF-Y; Louis-
Plence et al., 1997; Jabrane-Ferrat et al., 2002). This complex acts
as an enhanceosome driving transactivation of these genes (Mas-
ternak et al., 2000; Gobin et al., 2001; Choi et al., 2011). The
presence of the RFX components is crucial for the assembly of this
enhanceosome, a notion that has been derived from studies with
cell lines established from MHC-II deﬁciency patients (Reith and
Mach, 2001). In addition to these factors that assemble directly to
theX1,X2, andY-box sequences the class II transactivator (CIITA),
which acts as a co-activator, is also required. CIITA is essential for
MHC-II transcription (Steimle et al., 1993), while it contributes
to the activation of MHC-I promoters (Gobin et al., 1997; Martin
et al., 1997). CIITA belongs to the large NLR (nucleotide bind-
ing domain, leucine-rich repeat containing) family of proteins
that play multiple functions in innate immune responses (Har-
ton et al., 2002; Ting et al., 2008). Despite the fact that CIITA
activates MHC-I promoters in vitro, its in vivo contribution to
MHC-I gene transcription remained enigmatic. It is therefore
of note that more recently the NLR family member NLRC5 was
identiﬁed to associate with and activate the promoters of MHC-I
genes and not MHC-II genes in vivo (Meissner et al., 2010). Like
CIITA, NLRC5 also induced the expression of the gene encod-
ing β2-microglobulin. However, in contrast to CIITA, NLRC5 was
also found to control the expression of the genes encoding TAP
and LMP. These observations reveal that NLRC5 appears to be a
transcriptional regulator,which orchestrates the concerted expres-
sion of critical components in the MHC-I antigen presentation
pathway (Meissner et al., 2010).
Given the essential role of CIITA inMHC-II transcription, con-
stitutive expression of CIITA coincides with constitutive MHC-II
molecule expression in APCs. In non-immune cells expression of
CIITA can be induced by IFNγ resulting in inducible MHC-II
expression at the cell surface. CIITA therefore can be regarded as
a molecular switch for MHC-II expression. Transcriptional acti-
vation of MHC-II genes also involves modulation of covalent
histones modiﬁcations and chromatin remodeling (Choi et al.,
2011). As an example, IFNγ-induced MHC-II expression results
in an increase in active histone marks, i.e., acetylation of histone
H3 and H4, and 3meK4-H3 at the MHC-II promoter, while at the
same time a decrease in the repressive 3meK9-H3 histone mark is
noted (Chou and Tomasi, 2008).
CIITA TRANSACTIVATION AND EPIGENETIC ACTIVITIES
Class II transactivator exerts its transactivating function through
protein–protein interactions with the components of the MHC-
enhanceosome bound to the proximal SXY regulatory module in
MHC promoters (Figure 1; Masternak et al., 2000; Zhu et al.,
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2000; Jabrane-Ferrat et al., 2003). This interaction of CIITA with
the MHC-enhanceosome allows for the subsequent recruitment
of the lysine acetyltransferases (KATs) p300 (KAT3b)/CREB bind-
ing protein (CBP or KAT3a) and p300/CBP-associated factor
(PCAF or KAT2b), which promote transcription of MHC-I and
MHC-II genes by providing a more open chromatin structure
(Kretsovali et al., 1998; Fontes et al., 1999; Spilianakis et al.,
2000; Gobin et al., 2001). Furthermore, CIITA also recruits the
co-activator-associated argininemethyltransferase-1/protein argi-
nine N -methyltransferase 4 (CARM1/PRMT4; Zika and Ting,
2005; Zika et al., 2005; Figure 1). Besides acting as a platform
for recruitment of KAT activities, CIITA itself contains intrinsic
KAT activity. The CIITA-mediated transactivation of MHC pro-
moters was found to rely on this intrinsic KAT activity,whichmaps
to a region in its N-terminus (Raval et al., 2001). This KAT activ-
ity of CIITA is regulated by its C-terminal GTP-binding domain
and is stimulated by GTP (Raval et al., 2001). Interestingly, the
CIITAKAT activity was found to bypass TATAbox binding protein
(TBP)-associated factor 250 kDa (TAFII250) in MHC-I promoter
activation (Raval et al., 2001).Moreover, acetylation of CIITA itself
by CBP and/or PCAF at speciﬁc lysine residues within the bipartite
nuclear localization signal in the amino-terminal region of CIITA
governs its nuclear accumulation (Spilianakis et al., 2000).
Class II transactivator also interacts with histone deacetylases
(HDACs), which were found to interfere with CIITA function.
These activities that acetylate/deacetylate lysine residues act as
molecular switches for CIITA-mediated transcriptional activa-
tion/silencing of MHC genes. In this respect, it was found that
HDAC1 and HDAC2 interfere in the transcriptional transactiva-
tion function of CIITA following IFNγ induction (Zika et al., 2003;
Kong et al., 2009). In mice the HDAC1/HDAC2-associated repres-
sor SIN3 homolog A (mSin3A) ampliﬁes this inhibition in CIITA
function (Zika et al., 2003). HDAC2 has the potential to deacety-
late CIITA through its interaction with CIITA (Kong et al., 2009).
This results in targeting of CIITA to the proteasomal degrada-
tion machinery and decreased interaction of CIITA with the RFX
component RFX5 (Kong et al., 2009). Together, these observations
reveal that these HDAC activities affect CIITA function on the one
handbydisrupting assembly of theMHC-enhanceosome,while on
the other hand they interfere in CIITA interactions with theMHC-
enhanceosome. The switch/sucrose non-fermentable (SWI/SNF)
ATPaseBrahma-related gene-1 (BRG-1) also associateswithCIITA
and is required for the CIITA-mediated induction of MHC-II
genes (Mudhasani and Fontes, 2002). The association of CIITA
and BRG-1 suggest that the ATP-dependent chromatin remodel-
ing SWI/SNF complex is recruited by CIITA to MHC-II promoters
to control transcription of MHC-II genes. The ATPase Sug 1, a
component of the 19S proteasome (19S P) complex, was found to
be involved in increased levels of acetylation at MHC-II promot-
ers and appeared to be essential for CIITA stability and MHC-II
expression (Bhat et al., 2008, 2010a; Koues et al., 2008). More
recently, another subunit of the 19S proteosome complex, the
ATPase S6a (S6′/Tat-binding protein 1), was found to be crucial
for regulating cytokine-inducible transcription of CIITA thereby
indirectly modulation MHC-II transcription (Truax et al., 2010).
Other activities involvedmonoubiquitination of CIITA,whichwas
shown to stabilizeCIITAatMHC-II promoters (Bhat et al., 2010b).
In additionMLL/COMPASS subunits,which are involved in estab-
lishing active histone H3-K4 methylation marks, were found also
to be recruited to MHC-II promoters following IFNγ treatment
of cells (Koues et al., 2010; Figure 1).
LONG-RANGE PROMOTER INTERACTIONS
The appropriate temporal and spatial expression of MHC-II
genes in vivo also requires the involvement of additional, long-
range regulatory elements. The more distal X–Y or X-box like
sequences in the MHC-II region play an important role in these
processes (Gomez et al., 2005). It has been found that interactions
between the proximal elements and more distal X–Y or X-box like
sequences (2.3 kb upstream of the HLA-DRA promoter) result
in epigenetic changes at the MHC-II promoter (Masternak et al.,
2003; Wright and Ting, 2006; Choi et al., 2011). In one model,
RFX and CIITA can interact with the proximal SXY-module and
with distal X–Y or X-box like sequences to form a chromatin
loop (Masternak et al., 2003). This chromatin loop results in
enhanced histone acetylation (Krawczyk et al., 2004). Likewise,
the transcriptional insulator factor CCCTC binding factor insula-
tor (CTCF)was found to controlMHC-II gene expression through
long-distance chromatin interactions (Majumder et al., 2008).
The intergenic DNA of the HLA-DRB1 and HLA-DQA1 genes
hosts a region that was bound by CTCF and acts as a potent
enhancer-blocking element (Majumder et al., 2006). This element
and its bound factors were found to interact with HLA-DRB1 and
HLA-DQA1 (Majumder et al., 2008). Subsequently it was demon-
strated that CTCF associates with CIITA and RFX5 suggesting that
the CTCF bound region and the ﬂanking HLA-DRB1 and HLA-
DQA1 proximal promoters may interact (Majumder et al., 2008).
More recently it was shown by RNAi depletion of CTCF that all
CIITA-regulated genes within the MHC-II locus required CTCF
for maximal expression (Majumder and Boss, 2010).
EPIGENETIC REGULATION OF MHC2TA TRANSCRIPTION
Transcriptional regulation of MHC2TA, the gene encoding CIITA,
is mediated through the activity of four independent promoter
units (CIITA-PI through CIITA-PIV; Muhlethaler-Mottet et al.,
1997; Figure 2). These promoter units are employed in a cell
type- and activation-speciﬁc manner. CIITA-PI and CIITA-PIII
are used for the constitutive expression in dendritic cells and in B
cells, respectively (Muhlethaler-Mottet et al., 1997). CIITA-PIVhas
been shown to be the promoter predominantly involved in IFNγ-
inducible expression (Muhlethaler-Mottet et al., 1998; Piskurich
et al., 1998, 1999). In addition, in human non-B cells, CIITA-PIII
can also be activated by IFNγ through an element located 2 kb
upstream of the core CIITA-PIII promoter (Piskurich et al., 1999;
Van der Stoep et al., 2002a, 2007). CIITA-PIII has also been shown
to be employed by human T cells upon activation (Holling et al.,
2002; Wong et al., 2002). The promoter function of CIITA-PII is
still ill-deﬁned. The various MHC2TA promoters each transcribe a
unique ﬁrst exon and are located within a region of approximately
14 kb (Muhlethaler-Mottet et al., 1997).
Over the past years, several regulatory elements in MHC2TA
promoters and interacting factors that are important for transcrip-
tional activation have been identiﬁed (Figure 2). IFNγ-mediated
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FIGURE 2 | Schematic overview of the MHC2TA multi-promoter
region. Shown are the factors and elements governing
transactivation of CIITA-PI in immature dendritic cells, CIITA-PIII in B cells and
CIITA-PIV following IFNγ stimulation. The localization of the various
protein/DNA-binding elements is indicated relative to the transcription
start site.
activation of CIITA-PIV requires occupation of the gamma-
activated sequence (GAS)-box and the ISRE in CIITA-PIV by
STAT-1 and the STAT-1 target gene IRF-1 (Muhlethaler-Mottet
et al., 1998). Importantly, STAT-1 needs to interact with USF-1
bound to the E-box adjacent to the GAS-box for stable interaction
(Muhlethaler-Mottet et al., 1998; Figure 2). The IFNγ-mediated
activation of CIITA-PIV also results in increased histone H3 and
H4 acetylation at CIITA-PIV (Morris et al., 2002). Interestingly,
this increase in histone acetylation in CIITA-PIV chromatin is
already noted prior to recruitment of IRF-1 to the CIITA-PIV
promoter (Morris et al., 2002). In addition to the factors interact-
ing with these CIIT-PIV promoter elements, the SWI/SNF ATPase
BRG-1 was also found to be an important factor in the IFNγ-
mediated transcriptional activation of CIITA-PIV because cells
that lack expression of BRG-1 failed to induce CIITA expression
following exposure to IFNγ (Pattenden et al., 2002).
Class II transactivator-PIII is employed in B cells and activated
T cells in humans (Ghosh et al., 1999; Holling et al., 2002; Van
der Stoep et al., 2002a; Wong et al., 2002). Activation of CIITA-
PIII requires interaction of the transcription factor CREB-1 with
CRE-binding sites in the activation response element (ARE)-2
and, depending on the cellular context, also with CRE-binding
sites in the 5′-UTR of CIITA-PIII (Holling et al., 2002; Van der
Stoep et al., 2002a; Wong et al., 2002). The CREB-1 mediated acti-
vation of CIITA-PIII in B cells was ampliﬁed by the KAT CBP
(Van der Stoep et al., 2002a). CIITA-PIII also contains a com-
posite Ets/ISRE-consensus element (Site C) and 2 E-box motifs,
which were found to play a crucial role in its B cell-speciﬁc tran-
scriptional regulation (Van der Stoep et al., 2004). In B cells the
Ets/ISRE-consensus element is bound by PU.1 and IRF-4, whereas
the basic helix-loop-helix factor E47 interacts with the E-box
motifs.Whenbound respectively to the Ets/ISRE andE-boxes PU.1
and IRF-4, and E47 synergize to direct B cell-speciﬁc activation of
CIITA-PIII (Figure 2; Van der Stoep et al., 2004). The involvement
of these factors in B cell-speciﬁc activation of CIITA-PIII is of
interest because PU.1, IRF-4, and E47 also play an important role
in B cell differentiation and activation.
In vivo footprint analysis of CIITA-PI in immature dendritic
cells revealed multiple protein/DNA interactions that were lost
upon maturation of dendritic cells. CIITA-PI was found to con-
tain binding sites for PU.1, Sp-1 NF-κB, and a composite Ets/ISRE
(Figure 2; Smith et al., 2011). Transcription mediated by CIITA-PI
in immature dendritic cells requires binding of PU.1, IRF-8, NF-
κB, and Sp-1 to the promoter (Smith et al., 2011). Interestingly,
for binding of PU.1 to the composite Ets/ISRE heterodimeriza-
tion with IRF-8 is a prerequisite. Mutational analysis of the PU.1,
IRF-8, and NF-κB sites showed that these sites were critical for
transcriptional activity of CIITA-PI. Of note is also that mice lack-
ing IRF-8 displayed an unoccupied CIITA-PI, which was restored
by reconstitution with IRF-8 in vitro (Smith et al., 2011). Together,
these observations reveal an important role for PU.1/IRF-8 in the
activation of CIITA-PI in immature dendritic cells.
Plasma B cells lack expression of CIITA (Silacci et al., 1994).
This extinction of CIITA and resulting MHC-II molecule expres-
sion during differentiation of B cells into plasma B cells is
mediated by the transcriptional repressor B lymphocyte-induced
maturation protein-1 (Blimp-1, also known as positive regu-
latory domain I-binding factor 1, PRDI-BF1; Piskurich et al.,
2000; Ghosh et al., 2001). The silencing of CIITA expression in
plasma cells is most likely resulting from binding of Blimp-1 to
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the Ets/ISRE-consensus element in CIITA-PIII thereby disrupting
the interaction of PU.1/IRF-4 to this element (Piskurich et al.,
2000; Ghosh et al., 2001; Wright and Ting, 2006). Interestingly,
besides its repressive activity on CIITA-PIII transactivation, there
is more recent evidence that PRDI-BF1 mediates also repression
of CIITA-PIV (Chen et al., 2007). Transcriptional repression of
MHC2TA mediated by Blimp-1/PRDI-BF1 is also associated with
histone deacetylase and lysine methyltransferase (KMT) activities
(Yu et al., 2000; Gyory et al., 2004). In particular the activities
of the histone deacetylases HDAC1 and HDAC2, and the lysine
methyltransferase KMT1C (also known as G9a), are required in
these epigenetic silencingprocesses. Indeed itwas demonstrated by
chromatin immunoprecipitation (ChIP) that differences between
B cells and plasma cells exist in the levels of activating and repres-
sive histone marks in CIITA-PIII chromatin (Green et al., 2006).
In plasma cells lacking CIITA expression, histone marks associ-
ated with gene transcription such as acetylated histone H3 and
H4, and 2meK4-H3 and 3meK4-H3 are lost at CIITA-PIII, while
the repressive 2meK9-H3 mark is increased (Green et al., 2006).
Interestingly these histonemarkswere found also to exist at CIITA-
PI, CIITA-PII and CIITA-PIV, revealing the involvement of the
entire MHC2TA multi-promoter region. As a consequence of the
repressive histone marks and resulting chromatin inaccessibility,
the binding of CIITA-PIII interacting transcription factors (i.e.,
Sp-1, CREB-1, E47, PU.1, IRF-4) was lost in plasma cells (Green
et al., 2006).
In dendritic cell maturation chromatin remodeling also plays
an important role in the control of MHC2TA transcription (Land-
mann et al., 2001; Choi et al., 2009). During differentiation of
monocytes into immature dendritic cells the CIITA-PI isoform
is induced. In immature dendritic cells, MHC-II molecules are
largely retained in intracellular compartments. Upon maturation
of dendritic cells, the peptide/MHC-II complexes are assembled
and transported to the cell surface. The increase of transported
MHC-II molecules at the cell surface is accompanied by rapid
transcriptional silencing of MHC2TA in matured dendritic cells
(Landmann et al., 2001). Like in plasma B cells, the transcrip-
tional inactivation of CIITA-PI is also accompanied by global
histone deacetylation involving not only CIITA-PI but also CIITA-
PIII and CIITA-PIV (Landmann et al., 2001). In a mouse model
activation of CIITA-PI, during differentiation of monocytes into
dendritic cells by mGM-CSF, is accompanied by an increase in
the levels of acetylated histone H3 and H4 (Choi et al., 2009).
IL-10 could block the increase in histone H3 and H4 acetyla-
tion during differentiation resulting in inhibition of MHC2TA
transcription (Choi et al., 2009). Recently the involvement of
the transcriptional repressor PRD1-BF1/Blimp-1 in these CIITA-
PI silencing processes was revealed (Smith et al., 2011). It was
shown that during dendritic cell maturation binding to CIITA-
PI of the transcriptional activators PU.1, IRF-8, NF-κB, and Sp-1
is lost while at the same time the transcriptional repressor PRD1-
BF1/Blimp-1 and its associated co-repressorsKMT1CandHDAC2
are recruited to CIITA-PI (Smith et al., 2011). This results in
a loss of histone acetylation and acquisition of histone K9-H3
dimethylation and heterochromatin protein 1γ (HP1γ) at CIITA-
PI (Smith et al., 2011). Together, the transcriptional repressor
PRD1-BF1/Blimp-1 appears to play a central role in the extinction
of the various CIITA promoters and therefore can be regarded as
a central regulator of MHC-II antigen presentation (Smith et al.,
2011).
Distal elements and chromatin remodeling also play an essen-
tial role in the transcriptional regulation of MHC2TA (Ni et al.,
2008). Transcriptional activation of CIITA-PIV by IFNγ relies on
the interaction with distal elements at −50 and −8 kb (Ni et al.,
2008). Contact was also detected between elements at −50 and
−16 kb. In these long-range interactions, BRG-1, the ATPase dri-
ving the chromatin remodeling complex SWI-SNF (also called
BAF), was constitutively bound to sites at −50, −16, −8, and
+59 kb, and also CIITA-IV (Ni et al., 2008). Thus BRG-1 not
only is an important factor in the CIITA-mediated activation of
MHC-II genes, but also controls the transcriptional activation
of MHC2TA itself through long-range chromatin and promoter
interactions.
EXTINCTION OF MHC-II EXPRESSION IN CANCER
As discussed in the previous sections lack of MHC-II molecule
expression coincides with lack of detectable levels of CIITA. In
cancer the transcriptional silencing of MHC2TA and resulting
extinction of MHC-II gene expression is frequently noted (Mur-
phy and Tomasi, 1998; Yazawa et al., 1999; Meissner et al., 2008;
Berghuis et al., 2009). The silencing of CIITA is mostly mediated
by chromatin modiﬁcations involving methylation of DNA and
modiﬁcations of histones. The lack of CIITA expression in several
cancer types is associated with CpG dinucleotide methylation of
CIITA-PIV and of CIITA-PIII DNA (Morris et al., 2000; Van den
Elsen et al., 2000, 2003; Van der Stoep et al., 2002b; Holling et al.,
2004,2006;Morimoto et al., 2004; Satoh et al., 2004;De LermaBar-
baro et al., 2008; Meissner et al., 2008). Besides CpG dinucleotide
methylation, the lack of IFNγ-induced transcription of MHC2TA
is also associated with histone deacetylase activities (Magner et al.,
2000; Murphy et al., 2002; Holtz et al., 2003; Kanaseki et al., 2003;
Chou et al., 2005).
In a uveal melanoma tumor cell line it was demonstrated
for the ﬁrst time that histone methylation played an impor-
tant role in MHC2TA transcriptional silencing (Holling et al.,
2007). The strongly reduced expression levels of CIITA after
IFNγ-induction were found to correlate with high levels of
the repressive 3meK27-H3 histone modiﬁcation in CIITA-PIV
chromatin in the absence of CpG dinucleotide methylation of
CIITA-PIV DNA (Holling et al., 2007). Moreover, the KMTase
Enhancer of Zeste Homolog 2 (EZH2, or KMT6) was recruited
to relative high levels into CIITA-PIV chromatin (Holling et al.,
2007). KMT6 is the catalytic subunit of the polycomb repressive
complex 2 (PRC2), which plays an important role in transcrip-
tional silencing and maintenance of cellular identity. Consistent
with the transcriptional silent state of MHC2TA was the lack
of RNA polymerase II recruitment into CIITA-PIV chromatin
after IFNγ-induction (Holling et al., 2007). RNA interference-
mediated silencing of expression of KMT6 resulted in an incre-
ment in CIITA mRNA expression levels after IFNγ induction.
These observations suggest that KMT6 is involved in the tran-
scriptional downregulation of IFNγ-induced expression of CIITA
in uveal melanoma (Holling et al., 2007). Notably, the tran-
scriptional silencing of MHC2TA by histone methylation in the
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absence of CpG dinucleotide methylation is in line with the
observation that the 3meK27-H3 modiﬁcation pre-marks genes
for de novo methylation in cancer (Schlesinger et al., 2007). It
could therefore be argued that the epigenetic make-up of the
CIITA-PIV region in uveal melanoma reﬂects pre-marking for
de novo methylation of DNA, and that this reﬂects an interme-
diate epigenetic state of MHC2TA in the complete shut down of
MHC-II mediated antigen presentation functions. More recently,
lack of CIITA expression was also found associated with high
levels of the 3meK27-H3 repressive histone mark in the rela-
tive absence of activating histone acetylation and methylation
marks in CIITA-PIII chromatin in T leukemia cell lines lack-
ing MHC-II molecule expression (Van Eggermond et al., 2011).
In contrast, CIITA and MHC-II molecule expressing T lym-
phoma cells displayed the opposite phenotype. As detailed above,
in T leukemia cells these repressive histone marks were also
found to be associated with the other CIITA promoters in the
MHC2TA multi-promoter region, while the opposite was noted
for T lymphoma cells (Van Eggermond et al., 2011). The high
levels of the repressive histone mark 3meK27-H3 were accom-
panied by relative high levels of KMT6 at the various CIITA
promoters in T leukemia cells, while CIITA expressing T lym-
phoma cells displayed a general lack of KMT6 (Van Eggermond
et al., 2011). Additionally, in HeLa cervical carcinoma cells a
role for KMT6 in transcriptional silencing of IFNγ-inducible
expression of CIITA was also revealed (Mehta et al., 2011).
Together, these observations provide a clear link with expres-
sion of Polycomb Group proteins and transcriptional silencing of
MHC2TA and resulting lack of expression of MHC-II molecules
in cancer.
CONCLUSION
Constitutive and induced transcription of MHC-I and MHC-II
genes ismediated by a set of conserved regulatory elements in their
promoters and interacting transcription factors of which the SXY-
module is shared by both sets of genes. CIITAplays an essential role
in the control of constitutive and induced MHC-II gene transcrip-
tion through its interaction with the MHC-enhanceosome bound
to the conserved SXY-module inMHC-II promoters.When bound
to the MHC-enhanceosome, CIITA acts as a platform recruiting
various activities involved in histone acetylation/deacetylation and
methylation. CIITA is also central to recruitment of more gen-
eral chromatin remodeling activities and long-range chromatin
interactions of MHC-II promoters with distal elements. These
activities mediated by CIITA provide strict control of transcrip-
tion of these important immune genes. An additional level of
transcriptional control for MHC-II gene expression is at the level
of MHC2TA, the gene encoding CIITA, which is also tightly reg-
ulated by both genetic and epigenetic mechanisms. Because of
the involvement of epigenetic mechanisms in the transcriptional
control of MHC genes, deviations in these epigenetic mechanisms
as observed under pathological conditions such as in cancer and
autoimmune disease might provide an opportunity for pharma-
cological interference targeting the enzymes that modify DNA and
histones.
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